ADC Therapeutics secures $86.6M financing, restructures debt

ADC Therapeutics (ADCT) reported Q2 earnings with steady ZYNLONTA revenue at $18.6M and reduced net loss to $16.6M. The FDA raised safety concerns about a combination trial, creating regulatory uncertainty. The company cut operating expenses by 29% and has cash to last into 2028. Short interest is at 5.70% of the float.

ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for p

ADC Therapeutics (NYSE: ADCT) reported Q2 2026 net product revenue of $18.6M (vs. $18.1M in Q2 2025) and cash and cash equivalents of $219.1M as of June 30, 2026. The FDA held a pre-sBLA meeting on LOTIS-5; the company is assessing the regulatory path. LOTIS-7 enrollment is complete and data were submitted to ASH.

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

ADC Therapeutics (NYSE: ADCT) announced a strategic reorganization, planning to cut its global workforce by about 17% to generate annualized estimated savings of roughly $10M. The company said it is preparing for regulatory and clinical milestones, including an FDA pre-sBLA meeting in August 2026 and an sBLA submission in Q4 2026, plus full LOTIS-7 data by end-2026.

ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed/refractory DLBCL. The combo met the primary endpoint for progression-free survival (6.1 vs 4.7 months vs R-GemOx) and showed no detrimental overall survival impact, with higher response rates (58.1% vs 45.2%) and longer complete responses. Safety differed, with more serious events and Grade 5 events in the ZYNLONTA arm. Shares fell 49.68% to $1.55 premarket.